Source:http://linkedlifedata.com/resource/pubmed/id/18606901
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2008-7-24
|
| pubmed:databankReference | |
| pubmed:abstractText |
Vitamin D receptor activation is associated with improved survival in patients with chronic kidney disease, but the mechanism of this benefit is unclear. To better understand the effects of vitamin D on endothelial function, blood pressure, albuminuria, and inflammation in patients with chronic kidney disease (2 patients stage 2, remaining stage 3), we conducted a pilot trial in 24 patients who were randomly allocated equally to 3 groups to receive 0, 1, or 2 microg of paricalcitol, a vitamin D analog, orally for 1 month. Placebo-corrected change in flow mediated dilatation with a 1-microg dose was 0.5% and 0.4% with a 2-microg dose (P>0.2). At 1 month, the treatment:baseline ratio of high sensitivity C-reactive protein was 1.5 (95% CI: 1.1 to 2.1; P=0.02) with placebo, 0.8 (95% CI: 0.3 to 1.9; P=0.62) with a 1-microg dose, and 0.5 (95% CI: 0.3 to 0.9; P=0. 03) with a 2-microg dose of paricalcitol. At 1 month, the treatment:baseline ratio of 24-hour albumin excretion rate was 1.35 (95% CI: 1.08 to 1.69; P=0.01) with placebo, 0.52 (95% CI: 0.40 to 0.69; P<0.001) with a 1-microg dose, and 0.54 (95% CI: 0.35 to 0.83; P=0. 01) with a 2-microg dose (P<0.001 for between group changes). No differences were observed in iothalamate clearance, 24-hour ambulatory blood pressure, or parathyroid hormone with treatment or on washout. Thus, paricalcitol-induced reduction in albuminuria and inflammation may be mediated independent of its effects on hemodynamics or parathyroid hormone suppression. Long-term randomized, controlled trials are required to confirm these benefits of vitamin D analogs.
|
| pubmed:grant | |
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
1524-4563
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
52
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
249-55
|
| pubmed:meshHeading |
pubmed-meshheading:18606901-Aged,
pubmed-meshheading:18606901-Aged, 80 and over,
pubmed-meshheading:18606901-Albuminuria,
pubmed-meshheading:18606901-Dose-Response Relationship, Drug,
pubmed-meshheading:18606901-Drug Administration Schedule,
pubmed-meshheading:18606901-Ergocalciferols,
pubmed-meshheading:18606901-Female,
pubmed-meshheading:18606901-Follow-Up Studies,
pubmed-meshheading:18606901-Glomerular Filtration Rate,
pubmed-meshheading:18606901-Humans,
pubmed-meshheading:18606901-Inflammation Mediators,
pubmed-meshheading:18606901-Kidney Failure, Chronic,
pubmed-meshheading:18606901-Kidney Function Tests,
pubmed-meshheading:18606901-Male,
pubmed-meshheading:18606901-Middle Aged,
pubmed-meshheading:18606901-Probability,
pubmed-meshheading:18606901-Reference Values,
pubmed-meshheading:18606901-Risk Assessment,
pubmed-meshheading:18606901-Severity of Illness Index,
pubmed-meshheading:18606901-Treatment Outcome
|
| pubmed:year |
2008
|
| pubmed:articleTitle |
Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial.
|
| pubmed:affiliation |
Indiana University and VAMC, 1481 W 10th St, Indianapolis, IN 46202, USA. ragarwal@iupui.edu
|
| pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|